📰 Tissue Factor News
Tissue Factor News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Tissue Factor. Real-time updates on events, politics, business and more.
February 27, 2024
Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate VYVGART® was launched in September 2023 in China and we...
February 8, 2024
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer.
February 8, 2024
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Bladder Cancer.
June 6, 2022
Following an extension of its partnership agreement with PinotBio (Gyeonggi-do, Korea), a clinical-stage oncology-focused biotechnology company, Aptamer Group has announced the development of new drug conjugates for use as precision chemotherapeutics. Click to read more...
May 23, 2022
Investegate announcements from Aptamer Group PLC, Aptamer Group and PinotBio extend collaboration
February 28, 2022
/PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused...
February 18, 2022
EXEL earnings call for the period ending December 31, 2021.
September 29, 2021
- Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US Phase I/II trial with ADC designed to treat solid tumors - MRG004A selected for clinical development based